Cargando…

Metformin: current clinical applications in nondiabetic patients with cancer

Metformin is one of the most commonly used first-line oral medications for type 2 diabetes mellitus. Multiple observational studies, reviewed in numerous systematic reviews, have shown that metformin treatment may not only reduce the risk of cancer but may also improve the efficacy of cancer treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Kailin, Li, Yajun, Guo, Zhen, Zeng, Yong, Zhang, Wei, Wang, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066888/
https://www.ncbi.nlm.nih.gov/pubmed/32074084
http://dx.doi.org/10.18632/aging.102787
_version_ 1783505331609927680
author Chen, Kailin
Li, Yajun
Guo, Zhen
Zeng, Yong
Zhang, Wei
Wang, Hui
author_facet Chen, Kailin
Li, Yajun
Guo, Zhen
Zeng, Yong
Zhang, Wei
Wang, Hui
author_sort Chen, Kailin
collection PubMed
description Metformin is one of the most commonly used first-line oral medications for type 2 diabetes mellitus. Multiple observational studies, reviewed in numerous systematic reviews, have shown that metformin treatment may not only reduce the risk of cancer but may also improve the efficacy of cancer treatment in diabetic patients. Recent studies have been conducted to determine whether a similar protective effect can be demonstrated in nondiabetic cancer patients. However, the results are controversial. The potential optimal dose, schedule, and duration of metformin treatment and the heterogeneity of histological subtypes and genotypes among cancer patients might contribute to the different clinical benefits. In addition, as the immune property of metformin was investigated, further studies of the immunomodulatory effect of metformin on cancer cells should also be taken into account to optimize its clinical use. In this review, we present and discuss the latest findings regarding the anticancer potential of metformin in nondiabetic patients with cancer.
format Online
Article
Text
id pubmed-7066888
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Impact Journals
record_format MEDLINE/PubMed
spelling pubmed-70668882020-03-19 Metformin: current clinical applications in nondiabetic patients with cancer Chen, Kailin Li, Yajun Guo, Zhen Zeng, Yong Zhang, Wei Wang, Hui Aging (Albany NY) Review Metformin is one of the most commonly used first-line oral medications for type 2 diabetes mellitus. Multiple observational studies, reviewed in numerous systematic reviews, have shown that metformin treatment may not only reduce the risk of cancer but may also improve the efficacy of cancer treatment in diabetic patients. Recent studies have been conducted to determine whether a similar protective effect can be demonstrated in nondiabetic cancer patients. However, the results are controversial. The potential optimal dose, schedule, and duration of metformin treatment and the heterogeneity of histological subtypes and genotypes among cancer patients might contribute to the different clinical benefits. In addition, as the immune property of metformin was investigated, further studies of the immunomodulatory effect of metformin on cancer cells should also be taken into account to optimize its clinical use. In this review, we present and discuss the latest findings regarding the anticancer potential of metformin in nondiabetic patients with cancer. Impact Journals 2020-02-18 /pmc/articles/PMC7066888/ /pubmed/32074084 http://dx.doi.org/10.18632/aging.102787 Text en Copyright © 2020 Chen et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review
Chen, Kailin
Li, Yajun
Guo, Zhen
Zeng, Yong
Zhang, Wei
Wang, Hui
Metformin: current clinical applications in nondiabetic patients with cancer
title Metformin: current clinical applications in nondiabetic patients with cancer
title_full Metformin: current clinical applications in nondiabetic patients with cancer
title_fullStr Metformin: current clinical applications in nondiabetic patients with cancer
title_full_unstemmed Metformin: current clinical applications in nondiabetic patients with cancer
title_short Metformin: current clinical applications in nondiabetic patients with cancer
title_sort metformin: current clinical applications in nondiabetic patients with cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066888/
https://www.ncbi.nlm.nih.gov/pubmed/32074084
http://dx.doi.org/10.18632/aging.102787
work_keys_str_mv AT chenkailin metformincurrentclinicalapplicationsinnondiabeticpatientswithcancer
AT liyajun metformincurrentclinicalapplicationsinnondiabeticpatientswithcancer
AT guozhen metformincurrentclinicalapplicationsinnondiabeticpatientswithcancer
AT zengyong metformincurrentclinicalapplicationsinnondiabeticpatientswithcancer
AT zhangwei metformincurrentclinicalapplicationsinnondiabeticpatientswithcancer
AT wanghui metformincurrentclinicalapplicationsinnondiabeticpatientswithcancer